Does enteral XXXX supplementation decrease infectious morbidity?

@entity1 @entity281 @entity130 @entity1160
BACKGROUND: Although some studies have demonstrated lower infectious morbidity in @entity1 receiving supplemental @entity1160 , there remains no consensus on the utility of such treatment. This study was designed to investigate the effects of supplemental enteral @entity1160 on the rate and outcomes of @entity281 in critically ill surgical @entity1 . METHODS: All 185 surgical and @entity130 @entity1 admitted to a single university surgical @entity130 intensive care unit (STICU) over an approximately three-year period who were to receive enteral nutrition support were assigned sequentially to one of three diets: standard 1-kCal/mL feedings with added protein (Group 1), standard feedings with @entity1160 0.6 g/kg per day (Group 2), or immune-modulated feedings with a similar amount of @entity1160 (Group 3). Group compositions and @entity1 characteristics were similar at baseline. Data were collected prospectively on @entity281 acquired during hospitalization. RESULTS: A total of 119 @entity1 had at least one @entity281 : 59% of the @entity1 in Group 1, 64% of Group 2, and 69% of Group 3 (p = NS). There were no differences among the groups in the mean number of @entity281 . The most common sites in all groups were the lungs, blood, and urine; and the frequencies of these @entity281 did not differ between groups. Minor differences were found between groups in the organisms isolated. Antibiotic usage did not differ. CONCLUSION: Supplemental enteral @entity1160 in the dose studied does not appear to influence the acquisition or characteristics of @entity281 in @entity1 admitted to a mixed STICU.
